FDA has granted Fast Track designation for the development program of eltanexor as monotherapy for the treatment of patients with relapsed or refractory intermediate, high-, or very high-risk myelodysplastic syndromes (MDS).
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
